Mark Sleeman, PhD

Dr Sleeman has a combined background in neurobiology, endocrinology and biochemistry and he has published in journals such PNAS, Cell Metabolism and Nature Medicine, Genetics and Neuroscience. He is a leader within the field of metabolic research and his work has often challenged established theories in insulin signaling and diabetes (role of ChREBP, SHIP2 and Trb3) and at other times been seminal in expanding fields of research, such as for gut peptide ghrelin. Common to all studies is the combined use of mouse and human genomic approaches, gene expression analysis coupled with detailed physiological studies to understand primary mechanism of action. His leadership qualities are evident by the ability to simultaneously lead a discover research and therapeutic development team in a world-class biotechnology company.